4-ethynyl-1H-imidazole | 57121-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-ethynyl-1H-imidazole
• 英文别名: 5-Ethynyl-1H-imidazole
• CAS: 57121-48-9
• 化学式: C₅H₄N₂
• mdl: MFCD21336089
• 分子量: 92.1002
• InChiKey: BJXDBXQZKWQSBV-UHFFFAOYSA-N

物化性质

• 熔点：
  100.5-101 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))
• 沸点：
  293.5±13.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-ethynyl-1H-imidazole 、 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl chloride 以 苯 为溶剂， 以42%的产率得到1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl)-4-ethynylimidazole
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent

  摘要：

  To explore more potent N-acylimidazole analogues of CDDO than CDDO-Im, which is one of the most potent compounds in several widely used bioassays related to protection against inflammation and carcinogenesis; we have synthesized and evaluated five new N-acyl(acetylenic) imidazole analogues. Among them, 4-ethynylimidazole 4 is nearly equivalent to CDDO-Im in potency in these bioassays. Remarkably, the solid form of 4 is more stable than that of CDDO-Im. These findings suggest that 4 is a very promising anti-inflammatory and cytoprotective agent and its further preclinical evaluation is warranted. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.018
• 作为产物：
  描述：

  1-{[2-(trimethylsilyl)ethoxy]methyl}-4-[2-(trimethylsilyl)ethynyl]-1H-imidazole 在 水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 4-ethynyl-1H-imidazole
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent

  摘要：

  To explore more potent N-acylimidazole analogues of CDDO than CDDO-Im, which is one of the most potent compounds in several widely used bioassays related to protection against inflammation and carcinogenesis; we have synthesized and evaluated five new N-acyl(acetylenic) imidazole analogues. Among them, 4-ethynylimidazole 4 is nearly equivalent to CDDO-Im in potency in these bioassays. Remarkably, the solid form of 4 is more stable than that of CDDO-Im. These findings suggest that 4 is a very promising anti-inflammatory and cytoprotective agent and its further preclinical evaluation is warranted. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.018

文献信息

• [4 + 2]-Annulation of MBH-Acetates of Acetylenic Aldehydes with Imidazoles/Benzimidazoles To Access Imidazo[1,2-<i>a</i>]pyridines/Benzimidazo[1,2-<i>a</i>]pyridines
  作者：Chada Raji Reddy、Amarender Goud Burra

  DOI：10.1021/acs.joc.9b01118

  日期：2019.7.19

  developed to construct diversely substituted imidazo[1,2-a]pyridines and benzimidazo[1,2-a]pyridines in good to excellent yield. The advantage of this unique [4 + 2]-annulation lies in the employment of readily accessible starting materials, Morita–Baylis–Hillman acetates of acetylenic aldehydes as C4 synthons, and simple imidazoles or benzimidazoles as C2 synthons.

  前所未有的一锅连续碱介导的烯丙基胺化/环异构反应的策略已经被开发来构造不同地取代的咪唑并[1,2一]吡啶和苯并咪唑并[1,2一]在良好吡啶以优良的产率。这种独特的[4 + 2]环状结构的优势在于使用了易于获取的起始材料，即乙炔醛的Morita–Baylis–Hillman乙酸盐作为C4合成子，以及简单的咪唑或苯并咪唑作为C2合成子。
• [EN] FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS<br/>[FR] 1,4-OXAZÉPINES FUSIONNÉES UTILISÉES COMME AGENTS DE DÉGRADATION DE PROTÉINES BET
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018052945A1

  公开（公告）日：2018-03-22

  The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provids compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

  本公开提供由式I表示的化合物及其药用可接受的盐、水合物和溶剂化合物，其中R1、R2a、R2b、R3a、R3b、R4、Ar、L、X、Y和B的定义如规范中所述。本公开还提供了式I的化合物，用于治疗对BET溴结构域降解敏感的疾病或疾病，如癌症。
• [EN] FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS<br/>[FR] 1,4-DIAZÉPINES FUSIONNÉES EN TANT QU'AGENTS DE DÉGRADATION DE PROTÉINES BET
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018052949A1

  公开（公告）日：2018-03-22

  The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

  本公开提供由式I表示的化合物：I，及其药用可接受的盐、水合物和溶剂合物，其中R1、R2a、R2b、R3、R4、Ar、L、X、Y和B的定义如规范中所述。本公开还提供用于治疗对BET溴结构域降解敏感的疾病或疾病的式I化合物，如癌症。
• Structure-Based Discovery and Optimization of Furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors
  作者：Junhua Li、Cheng Zhang、Hongrui Xu、Chao Wang、Ruibo Dong、Hui Shen、Xiaoxi Zhuang、Xiaoshan Chen、Qiu Li、Jibu Lu、Maofeng Zhang、Xishan Wu、Kerry M. Loomes、Yulai Zhou、Yan Zhang、Jinsong Liu、Yong Xu

  DOI：10.1021/acs.jmedchem.2c00100

  日期：2022.4.14

  selectivity over BRD4 BD1. Besides, 8l exhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound 8l displayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC50 = 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors. 8l also demonstrated

  泛溴结构域和额外末端 (Pan-BET) 抑制剂显示出深远的疗效，但在临床试验中表现出药理学驱动的毒性。迫切需要开发域选择性 BET 抑制剂来区分疗效和毒性。在此，我们报告了一系列作为新型 BD2 选择性 BET 抑制剂的 furo[3,2 - c ]pyridin-4(5 H )-one 衍生物。代表性化合物8l (XY153) 与 BRD4 BD2 有效结合，半数最大抑制浓度 (IC 50 ) 值为 0.79 nM，并显示出比 BRD4 BD1 高 354 倍的选择性。此外，8l表现出比其他 BET BD2 结构域高 6 倍的 BRD4 BD2 结构域选择性。化合物8l对多种肿瘤细胞系显示出有效的抗增殖活性，尤其是 MV4-11 (IC 50 = 0.55 nM)，同时对正常肺成纤维细胞系显示出较弱的细胞毒性。它突出了这一系列 BD2 抑制剂的安全性。8l还表现出良好的体外代谢稳定性。
• A Stereospecific Route to (<i>Z</i>)-Urocanic Acids
  作者：Hamish McNab、Xavier Despinoy、Richard Tyas

  DOI：10.1055/s-2008-1067044

  日期：2008.6

  ( Z)-Urocanic acid and its derivatives can be made stereo-specifically by ring-opening of pyrrolo[1,2- C]imidazol-5-ones in aqueous tetrahydrofuran.

  (Z)-尿烷酸及其衍生物可以通过吡咯并[1,2-C]咪唑-5-酮在水性四氢呋喃中的开环反应制备立体特异性。